### What is needed
- To improve management of TB patients with faster more accurate diagnostic tools
- To better understand global burden of TB
- To optimize and ensure the effectiveness of new TB drug regimens

### Goal
The Relational Sequencing TB Data Platform (ReSeqTB) will serve as a single globally harmonized repository for the compilation, curation and validation of existing and newly created data on TB drug resistance correlations.

### Who it will impact
- Diagnostic test developers: Provide a validated set of genetic polymorphisms known to be associated with drug resistance to drugs used to treat TB
- Clinical management: Provide clarity on interpreting clinical relevance and treatment decisions of different genetic mutations
- Research community: Provide a resource to explore novel mutations that may be associated with drug resistance of existing and new drugs

### Our Collaborative Partnership

- **CRITICAL PATH INSTITUTE**
  - C-Path has 10 years of experience with the design and implementation of global data platforms in nine major disease areas, representing data from more than 30,000 patients and growing.

- **FIND**
  - Over the past 12 years, FIND collaborations have led to the delivery of 11 new diagnostic tools, created an enabling environment for countless more through specimen banks, reagent development and increased market visibility, and supported scale-up of diagnostics through quality assurance and lab strengthening.

- **World Health Organization**
  - The WHO Global TB Programme aims to advance universal access to TB prevention, care and control, guide the global response to threats, and promote innovation.

- **CDC Division of Tuberculosis Elimination**
  - The mission of the CDC Division of Tuberculosis Elimination (DTBE) is to promote health and quality of life by preventing, controlling, and eventually eliminating tuberculosis from the United States by collaborating with other countries and international partners in controlling global tuberculosis.

- **New Diagnostics Working Group (NDWG)**
  - As a Stop TB Partnership working group, the New Diagnostics Working Group (NDWG) is a network of global experts representing academia, governmental and technical agencies, NGOs, diagnostic manufacturers, national TB programs and the patient community. The mission of the NDWG is to foster development and evaluation of new TB diagnostics by serving as a coordination, communication, and advocacy platform for effective collaboration of all stakeholders in TB diagnostic research and development.

- **The National Institute of Allergy and Infectious Diseases (NIAID)**
  - The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

---

For further information and updates, please visit: [http://www.cptrinitiative.org/about/rapid-drug-susceptibility-testing/](http://www.cptrinitiative.org/about/rapid-drug-susceptibility-testing/)